1. EXECUTIVE SUMMARY
1.1. MARKET OVERVIEW
1.2. KEY FINDINGS
1.3. MARKET SEGMENTATION
1.4. COMPETITIVE LANDSCAPE
1.5. CHALLENGES AND OPPORTUNITIES
1.6. FUTURE OUTLOOK
2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. SCOPE OF THE STUDY
2.2.1. RESEARCH OBJECTIVE
2.2.2. ASSUMPTION
2.2.3. LIMITATIONS
3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING MODEL
3.6. MARKET SIZE ESTIMATION
3.6.1. BOTTOM-UP APPROACH
3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION
4. MARKET DYNAMICS
4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES
5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.2. PORTER'S FIVE FORCES ANALYSIS
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. MARKET IMPACT ANALYSIS
5.3.2. REGIONAL IMPACT
5.3.3. OPPORTUNITY AND THREAT ANALYSIS
6. MOLECULAR CLONING MARKET, BY TECHNIQUE (2025-2033)
6.1. RESTRICTION FRAGMENT LENGTH POLYMORPHISM
6.2. POLYMERASE CHAIN REACTION
6.3. RECOMBINANT DNA TECHNOLOGY
6.4. DNA SEQUENCING
6.5. GEL ELECTROPHORESIS
7. MOLECULAR CLONING MARKET, BY APPLICATION (2025-2033)
7.1. THERAPEUTICS
7.2. GENETIC ENGINEERING
7.3. AGRICULTURAL BIOTECHNOLOGY
7.4. SYNTHETIC BIOLOGY
8. MOLECULAR CLONING MARKET, BY END USER (2025-2033)
8.1. ACADEMIC RESEARCH INSTITUTIONS
8.2. PHARMACEUTICAL COMPANIES
8.3. BIOTECHNOLOGY COMPANIES
8.4. CONTRACT RESEARCH ORGANIZATIONS
9. MOLECULAR CLONING MARKET, BY PRODUCT (2025-2033)
9.1. ENZYMES
9.2. VECTOR SYSTEMS
9.3. CLONING KITS
9.4. COMPETENT CELLS
10. MOLECULAR CLONING MARKET, BY REGIONAL (2025-2033)
10.1. NORTH AMERICA
10.1.1. US
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. UK
10.2.3. FRANCE
10.2.4. RUSSIA
10.2.5. ITALY
10.2.6. SPAIN
10.2.7. REST OF EUROPE
10.3. APAC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. MALAYSIA
10.3.6. THAILAND
10.3.7. INDONESIA
10.3.8. REST OF APAC
10.4. SOUTH AMERICA
10.4.1. BRAZIL
10.4.2. MEXICO
10.4.3. ARGENTINA
10.4.4. REST OF SOUTH AMERICA
10.5. MEA
10.5.1. GCC COUNTRIES
10.5.2. SOUTH AFRICA
10.5.3. REST OF MEA
11. COMPETITIVE LANDSCAPE
11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE MOLECULAR CLONING MARKET
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE MOLECULAR CLONING MARKET
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
11.7.2. MERGER & ACQUISITIONS
11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
11.8.1. SALES AND OPERATING INCOME
11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023
12. COMPANY PROFILES
12.1. THERMO FISHER SCIENTIFIC
12.1.1. FINANCIAL OVERVIEW
12.1.2. PRODUCTS OFFERED
12.1.3. KEY DEVELOPMENTS
12.1.4. SWOT ANALYSIS
12.1.5. KEY STRATEGIES
12.2. SIGMA-ALDRICH
12.2.1. FINANCIAL OVERVIEW
12.2.2. PRODUCTS OFFERED
12.2.3. KEY DEVELOPMENTS
12.2.4. SWOT ANALYSIS
12.2.5. KEY STRATEGIES
12.3. CLONTECH LABORATORIES
12.3.1. FINANCIAL OVERVIEW
12.3.2. PRODUCTS OFFERED
12.3.3. KEY DEVELOPMENTS
12.3.4. SWOT ANALYSIS
12.3.5. KEY STRATEGIES
12.4. QIAGEN
12.4.1. FINANCIAL OVERVIEW
12.4.2. PRODUCTS OFFERED
12.4.3. KEY DEVELOPMENTS
12.4.4. SWOT ANALYSIS
12.4.5. KEY STRATEGIES
12.5. AGILENT TECHNOLOGIES
12.5.1. FINANCIAL OVERVIEW
12.5.2. PRODUCTS OFFERED
12.5.3. KEY DEVELOPMENTS
12.5.4. SWOT ANALYSIS
12.5.5. KEY STRATEGIES
12.6. NEW ENGLAND BIOLABS
12.6.1. FINANCIAL OVERVIEW
12.6.2. PRODUCTS OFFERED
12.6.3. KEY DEVELOPMENTS
12.6.4. SWOT ANALYSIS
12.6.5. KEY STRATEGIES
12.7. BIOTECHNOLOGY COMPANY
12.7.1. FINANCIAL OVERVIEW
12.7.2. PRODUCTS OFFERED
12.7.3. KEY DEVELOPMENTS
12.7.4. SWOT ANALYSIS
12.7.5. KEY STRATEGIES
12.8. ADDGENE
12.8.1. FINANCIAL OVERVIEW
12.8.2. PRODUCTS OFFERED
12.8.3. KEY DEVELOPMENTS
12.8.4. SWOT ANALYSIS
12.8.5. KEY STRATEGIES
12.9. SANGAMO THERAPEUTICS
12.9.1. FINANCIAL OVERVIEW
12.9.2. PRODUCTS OFFERED
12.9.3. KEY DEVELOPMENTS
12.9.4. SWOT ANALYSIS
12.9.5. KEY STRATEGIES
12.10. MERCK KGAA
12.10.1. FINANCIAL OVERVIEW
12.10.2. PRODUCTS OFFERED
12.10.3. KEY DEVELOPMENTS
12.10.4. SWOT ANALYSIS
12.10.5. KEY STRATEGIES
12.11. GENSCRIPT
12.11.1. FINANCIAL OVERVIEW
12.11.2. PRODUCTS OFFERED
12.11.3. KEY DEVELOPMENTS
12.11.4. SWOT ANALYSIS
12.11.5. KEY STRATEGIES
12.12. TAKARA BIO
12.12.1. FINANCIAL OVERVIEW
12.12.2. PRODUCTS OFFERED
12.12.3. KEY DEVELOPMENTS
12.12.4. SWOT ANALYSIS
12.12.5. KEY STRATEGIES
12.13. PROMEGA CORPORATION
12.13.1. FINANCIAL OVERVIEW
12.13.2. PRODUCTS OFFERED
12.13.3. KEY DEVELOPMENTS
12.13.4. SWOT ANALYSIS
12.13.5. KEY STRATEGIES
12.14. ILLUMINA
12.14.1. FINANCIAL OVERVIEW
12.14.2. PRODUCTS OFFERED
12.14.3. KEY DEVELOPMENTS
12.14.4. SWOT ANALYSIS
12.14.5. KEY STRATEGIES
13. APPENDIX
13.1. REFERENCES
13.2. RELATED REPORTS
著作権 ©2022 無断複写・転載を禁じます
